We found that CHK2 protein-modifying alterations were associated with worse progression-free survival (PFS) of NHL patients overall (i.e., regardless of histology type; HRPFS = 2.1; P = 0.02; Fig 2A), and that the association was even stronger for carriers of the missense variant I157T compared with any other genotype (i.e. I157T vs. mutation-free or any other alteration; HRPFS = 3.7 P = 0.007; Fig 2B). Here, CHEK2 is linked to non-Hodgkin lymphoma.